Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Emily C AyersShaoying LiL Jeffrey MedeirosDavid A BondKami J MaddocksPallawi TorkaAngel Mier HicksMadeira CurryNina D Wagner-JohnstonReem KarmaliAmir BehdadBita FakhriBrad S KahlMichael C ChurnetskiJonathon B CohenNishitha M ReddyDipenkumar ModiRadhakrishnan RamchandrenChristina HowlettLori A LeslieSamuel CytrynCatherine S DiefenbachRawan FaramandJulio C ChavezAdam J OlszewskiYang LiuStefan K BartaDhruvika MukhijaBrian T HillHelen MaJennifer E AmengualSunita NathanSarit E AssoulineVictor M Orellana-NoiaCraig A PortellAshwin ChandarKevin A DavidAnshu GiriBrian T HessDaniel J LandsburgPublished in: Cancer (2019)
Patients with early treatment failure after intensive first-line immunochemotherapy experience poor outcomes after receiving standard second-line immunochemotherapy. The use of standard-of-care or experimental therapies currently available in the third-line setting and beyond should be investigated in the second-line setting for these patients.